Polo-like kinase
Impact of Polo-like kinase 1 inhibitors on human adipose tissue- derived mesenchymal stem cells
15
Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma
14
Immunohistochemical detection of Polo like kinase 1 (PLK1) in primary breast cancer is associated with TP53mutation and poor clinical outcome
11
Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy
14
Original Article Polo-like kinase 1 controls cell proliferation regulated by miR-296-5p in ovarian cancer
8
Mumps Virus Nucleoprotein Enhances Phosphorylation of the Phosphoprotein by Polo-Like Kinase 1
11
Polo-like kinase 4 at the nexus of epigenetic modifications and the DNA damage signaling network
217
Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1)
11
The activity regulation of the mitotic centromere-associated kinesin by Polo-like kinase 1
15
Polo-Like Kinase Guides Cytokinesis in Trypanosoma brucei through an Indirect Means
12
Polo-like kinase 1 (Plk1): an Unexpected Player in DNA Replication
7
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors
11
<p>Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers</p>
14
Exploration of Mutation and DNA Methylation of Polo Like Kinase 1 (PLK1) in Colorectal Cancer
13
Polo-Like Kinase 1 Is Involved in Hepatitis C Virus Replication by Hyperphosphorylating NS5A
11
Henipavirus V Protein Association with Polo-Like Kinase Reveals Functional Overlap with STAT1 Binding and Interferon Evasion
13
A TAT-conjugated peptide inhibitor of polo-like kinase 1 for in vivo tumor imaging
8
Habedanck, Robert (2006): The Human Polo-like Kinase 4 is a Regulator of Centrosome Duplication. Dissertation, LMU München: Fakultät für Biologie
124
Loss of p21 Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition
16
Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells
10